The second-generation Covid-19 vaccine from GlaxoSmithKline (GSK) and its associate CureVac induces a stronger immune response than the German biotech’s first vaccine, according to a new study.
In an animal-based study, which has yet to be peer-reviewed, the companies said the mRNA vaccine could induce antibodies competent of tackling several variants of concern, including Beta, Delta and Lambda, the company said in a statement on Monday. The results of the study, which were released on Monday, came as CureVac’s losses widened in the second quarter. The German group has been investing heavily in the development of vaccines and expanding production for the first-generation vaccine.
CureVac's first mRNA-based Covid vaccine CVnCoV, showed the efficacy of just 47 percent, the lowest reported so far from any Covid-19 vaccine maker. The new study assessed cynomolgus macaques vaccinated with 12 microgram of either the first or second-generation vaccine candidate. Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV.
Study suggests regular exercise even in polluted areas may cut mortality risk
Study finds: New Protein-Based Covid Vaccine Mimics Virus Shape to Provide Robust Antibody Response
Single-dose of Pfizer vaccine may be sufficient for people who have had COVID: study